mavrostobart + gemcitabine + nab-paclitaxel

This is an experimental **combination regimen** of three drugs: - **Mavrostobart (PT199)**, an anti-CD73 monoclonal antibody currently in Phase I/II studies, is designed to fully inhibit CD73 enzyme activity, thereby blocking adenosine-mediated immunosuppression in the tumor microenvironment and enhancing anti-tumor immune responses. - **Gemcitabine** is a nucleoside analog antimetabolite that inhibits DNA synthesis, commonly used as chemotherapy for pancreatic and other cancers. - **Nab-paclitaxel** is a nanoparticle albumin-bound formulation of paclitaxel, a microtubule inhibitor, developed to improve delivery and reduce solvent-related toxicity associated with conventional paclitaxel. This combination leverages CD73 inhibition to increase immune activity, while gemcitabine and nab-paclitaxel provide cytotoxic effects. It is under clinical evaluation for metastatic pancreatic and other advanced solid tumors, particularly in settings where CD73 is implicated in immune evasion[1][2][3][4][5][6].

Brand names

Abraxane (nab-paclitaxel)

Other names

albumin-bound paclitaxel (nab-paclitaxel)